language_icon
EN
HI

Astec Lifesciences Share price

ASTEC

740.6

42.50 (6.09%)
NSE
BSE
Last updated on 22 Apr, 2026 | 15:58 IST
Today's High

746.00

Today's Low

697.80

52 Week Low

513.40

52 Week High

988.51

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Astec Lifesciences Chart

Astec Lifesciences Share Key Metrics

Volume
2.02 L
Market Cap
1650.22 CR
LTQ@LTP
3@740.60
ATP
736.61
Var Margin
50 %
Circuit Range
558.5-837.7
Delivery %
36.69 %
Value
14.89 CR
ASM/GSM
No
Market Lot
1

Summary

22 Apr, 2026 | 15:58 को, Astec Lifesciences का शेयर प्राइस आज ₹740.6 पर है, जो दिन के लिए 42.50% की 6.09 दर्शाता है। स्टॉक की इंट्राडे मूवमेंट ₹697.80 और ₹746.00 के बीच रही है, जबकि 52‑सप्ताह के आधार पर यह ₹513.40 से ₹988.51 तक रही है। ट्रेडिंग गतिविधि के मामले में, Astec Lifesciences ने 202085 शेयरों का वॉल्यूम रिकॉर्ड किया है, जिसका मार्केट कैपिटलाइज़ेशन ₹22282238 है। स्टॉक की एवरेज ट्रेडेड प्राइस ₹73661 है, जबकि लास्ट ट्रेडेड क्वांटिटी एट लास्ट ट्रेडेड प्राइस (LTQ@LTP) 3,74060 रही। यह स्टॉक ₹558.5-837.7 की सर्किट रेंज में ट्रेड करता है, और आज का कारोबार मूल्य ₹14.89 CR है। दिन के लिए डिलीवरी परसेंटेज 36.69% रही। इसके अतिरिक्त, Astec Lifesciences वर्तमान में No फ्रेमवर्क के तहत आता है और 1 के मार्केट लॉट साइज़ में ट्रेड करता

Astec Lifesciences Fundamentals

View More
P/E Ratio

0

P/B Ratio

3.91

Div. Yield

0

Sector P/E

39.52

Sector P/B

2.22

Sec. Div. Yield

0.34

Astec Lifesciences Resistance and Support

Pivot 702.7

Resistance

First Resistance

713.4

Second Resistance

728.7

Third Resistance

739.4

Support

First Support

687.4

Second Support

676.7

Third Support

661.4

Astec Lifesciences Shareholding Pattern

View More
  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

71.97%

Mutual Fund

3.02%

Insurance

0%

Foreign Institutional Investors

0.04%

Domestic Institutional Investors

0.15%

Retail

24.82%

Others

0%

Total Promoters
MAR '25
70.87%
JUN '25
70.87%
SEP '25
72.42%
DEC '25
71.97%

Astec Lifesciences Corporate Actions

DateAgenda
2026-04-27Audited Results
2026-01-30Quarterly Results

Astec Lifesciences News

Astec LifeSciences Limited

Astec Lifesciences Limited will hold a board meeting on April 27, 2026, to consider and approve its audited yearly standalone and cons. financial results for the fiscal year ended March 31, 2026. The trading window for the company's shares is closed from April 1 to April 29, 2026.
Apr 17 2026 22:04:00

Astec LifeSciences Limited

Astec Lifesciences Limited will hold a board meeting on April 27, 2026, to consider and approve its audited yearly standalone and cons. financial results for the fiscal year ended March 31, 2026. The trading window for the company's shares is closed from April 1 to April 29, 2026.
Apr 17 2026 22:04:00

Astec LifeSciences Limited

Astec Lifesciences Limited will hold a board meeting on April 27, 2026, to consider and approve its audited yearly standalone and cons. financial results for the fiscal year ended March 31, 2026. The trading window for the company's shares is closed from April 1 to April 29, 2026.
Apr 17 2026 22:04:00

Astec Lifesciences Ltd - 533138 - Board Meeting Intimation for Approval Of Financial Results

Astec LifeSciences board to meet on April 27, 2026, to consider and approve the standalone and consolidated audited financial results for Q4 FY26 and the financial year ended March 31, 2026. These results will be reviewed by the Audit Committee prior to the board meeting.
Apr 17 2026 22:04:00

Astec LifeSciences Limited

Astec LifeSciences board is scheduled to meet on April 27, 2026. The meeting will consider and approve the standalone and consolidated audited financial results for Q4 and FY26, after review by the Audit Committee.
Apr 17 2026 21:04:00

Astec LifeSciences Limited

Astec LifeSciences confirmed timely payment of ₹25 crore for its Commercial Paper, Astec-CP-188, ensuring compliance with its financial obligations. The payment was made on the maturity date of April 15, 2026.
Apr 15 2026 18:04:00

Astec LifeSciences Limited

Astec LifeSciences announced significant management changes. Burjis Godrej transitioned from his role as Managing Director to an Additional Director Non Executive, effective April 13, 2026. Concurrently, Arijit Mukherjee, the Chief Operating Officer, was formally appointed to his role, strengthening the operational leadership.
Apr 15 2026 15:04:00

Astec LifeSciences Limited

Astec LifeSciences board approved significant leadership changes. Nadir Godrej retired as Chairman, while Vishal Sharma was appointed as the new Chairman. Burjis N. Godrej resigned as MD but was re-appointed as Non-Executive Director, alongside new appointments Mathew Eipe and Arijit Mukherjee.
Apr 13 2026 21:04:00

Astec LifeSciences Limited

Astec LifeSciences board approved significant leadership changes. Nadir Godrej retired as Chairman, while Vishal Sharma was appointed as the new Chairman. Burjis N. Godrej resigned as MD but was re-appointed as Non-Executive Director, alongside new appointments Mathew Eipe and Arijit Mukherjee.
Apr 13 2026 21:04:00

Astec LifeSciences Limited

Astec LifeSciences announced significant board changes effective April 13, 2026, including Nadir Godrej's retirement as Chairperson and the appointment of Vishal Sharma to lead the board. Burjis N. Godrej stepped down as MD but will continue as a Non-Executive Director, alongside Arijit Mukherjee's new role as Executive Director & COO, pending shareholder approval.
Apr 13 2026 18:04:00
Read More

About Astec Lifesciences AboutThe

NSE : 17728  
BSE : 533138  
ISIN : INE563J01010  

Our Company was incorporated on January 25 1994 under the Companies Act 1956 as UrshilaTraders Private Limited. Our Company was originally promoted by Mrs. Reena Bagai and Mrs.Avita Fernandes. Their shareholding was purchased by Mr. Ashok V Hiremath and Mr. PratapGarud on February 11 1994. The name of our Company was changed to Astec Chemicals PrivateLimited on August 19 1994 and further to Astec LifeSciences Private Limited on March 3 2006.With effect from April 27 2006 Astec LifeSciences Private Limited was converted into a publiclimited company under the name of "Astec LifeSciences Limited".We carry out our manufacturing activities at two locations in Maharashtra India comprising ofthree units in Maharashtra viz. one unit at Dombivli and two units at Mahad (Unit 1 and Unit 2).We started our first manufacturing unit in August 1994 by acquiring a sick unit in DombivliMaharashtra having an installed capacity of 120 MT for the manufacture of Dicap apharmaceutical intermediate.With a view to expand our operations we entered into an agreement with Behram ChemicalsPrivate Limited on February 18 2002 for using and operating their manufacturing facilities locatedat B-16 Mahad Industrial Area Sub-District Mahad District Raigad Maharashtra. BehramChemicals Private Limited was engaged in manufacture of chemicals and pesticides having aninstalled capacity of 130 MT.Behram Chemicals Private Limited was initially promoted by Mr. Jehangir J. Mistry Mrs. Villoo J.Mistry Mrs. Kamla G. Sippy and Mr. Surinder Kumar Verma in April 1993. During August 1998further shares were allotted to M.C. Chemicals and some members of Gangani family viz. Mr.Nasrudin K Gangani Mr. S. N. Gangani Mrs. N. N. Gangani Mr. T. K. Gangani and Khoja BoneMills Private Limited (a company promoted by Gangani family). Looking at the potential inBehram Chemicals Private Limited our Company have acquired 65.63% share by entering intoShare Purchase Agreement with the above members of Gangani family on April 2 2007. Mr.Jehangir J. Mistry Mrs. Villoo J. Mistry Mrs. Kamla G. Sippy and Mr. Surinder Kumar VermaM.C. Chemicals and Gangani family are not related to our Promoters / our Directors in anymanner in any capacity whatsoever. With this acquisition Behram Chemicals Private Limitedbecame a subsidiary of our Company. During 2003-04 we expanded total installed capacity of our units (Dombivli and Mahad) from 250MT to 500 MT. We renewed the agreement on August 1 2004 for a further period of 66 monthsending on January 31 2010. For more details in respect of the current agreement.In 2004 we acquired a plot located at B-17 Mahad Maharashtra and set up a new manufacturingfacility as an Export Oriented Unit (EOU) in the year 2005 (as Unit 2) which is located adjacent toUnit 1 with an installed capacity of 1000 MT. With the commissioning of Unit 2 our total installedcapacity increased to 1500 MT. We further expanded our total capacities to 2000 MT during 2006-07 and to 2500 MT during 2007-08.Our Company is primarily involved in the production of active ingredients and intermediates foragrochemicals and pharmaceutical segment. Hexaconazole Tebuconazole Metalaxyl andPropiconazole are some of our key products in agrochemical segment which are generally used incrop protection and Dicap is one of our key Pharmaceutical intermediate which is used inmanufacture of antifungal agents. Triazole fungicides which includes HexaconazoleTebuconazole and Propiconazole is one of our major product in the agrochemical segment andhas contributed 63.67% to our total sales whereas Dicap a key product in pharmaceutical segmenthas contributed 9.01% during FY 2007-08.Major events of our CompanyPeriod EventsJanuary 1994 Incorporation of Urshila Traders Private LimitedAugust 1994 Change of name to Astec Chemicals Private LimitedAugust 1994 Commenced first manufacturing unit at Dombivli MaharashtraMay 2001 Certified ISO 9002 by International Standards Certification Pty Limited AustraliaFebruary 2002 Entered into an agreement with Behram Chemicals Private LimitedMarch 2005 Re-certified ISO 9001:2000 by International Standards Certification Pty Limited AustraliaMay 2005 Commenced another manufacturing unit (Unit 2) as Export Oriented Unit at Mahad MaharashtraMarch 2006 Change of name to Astec LifeSciences Private LimitedApril 2006 Conversion of our Company from a private limited company to a public limited company January 2007 Established Astec Europe in Tournai BelgiumApril 2007 Behram Chemicals Private Limited became our subsidiary by acquisition of 65.63% vide Share Purchase Agreement dated April 2 2007

Read More

Astec Lifesciences Management

NamePosition
Tejashree PradhanCompany Secretary & Compliance Officer
Nadir B GodrejChairman
View More

Astec Lifesciences FAQs

Astec Lifesciences शेयर का खरीद मूल्य 740.6 है। लाइव प्राइस और तत्काल ट्रेडिंग के लिए, आप अपने चॉइस ट्रेडिंग खाते में लॉगिन कर सकते हैं या चॉइस के साथ मुक्त डीमैट खाता खोल सकते हैं।

Astec Lifesciences शेयर खरीदने के लिए अपने चॉइस ट्रेडिंग खाते में लॉगिन करें, या चॉइस डीमैट खाता खोल, फिर फंड जोड़ें, कंपनी का नाम खोजें, अपना ऑर्डर टाइप चुनें और ट्रेड प्लेस करें।

Astec Lifesciences शेयर का प्राइस-टू-अर्निंग्स (पी/ई) रेशियो 0 है। आप सापेक्ष मूल्यांकन के लिए इसकी तुलना सेक्टर के औसत से कर सकते हैं।

Astec Lifesciences शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 3.91 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Astec Lifesciences शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 2.22 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Astec Lifesciences का मार्केट कैप 1650.22 CR है। यह कंपनी के आकार की श्रेणी और ट्रेडिंग लिक्विडिटी को दर्शाता है।

Astec Lifesciences शेयर का 52 सप्ताह का उच्चतम और न्यूनतम मूल्य 988.51 और 513.40 है। ये मूल्य मूल्य सीमाएं, ट्रेडिंग रेंज, अस्थिरता, संभावित सपोर्ट/रेजिस्टेंस और मूल्य गति को दर्शाते हैं।

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost